Related Experiment Video
Updated: Aug 20, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Scoring atopic dermatitis in infants and young children: distinctive features of the SCORAD index
N Pucci1, E Novembre, M G Cammarata
1Allergy and Clinical Immunology Unit, Department of Paediatrics, Anna Meyer Children's Hospital, University of Florence, Florence, Italy.
Insights
This study shows a strong correlation between skin involvement, severity, and symptoms in infants and young children with atopic dermatitis (AD). Immunologic markers also align with SCORAD index scores, validating its use for assessing AD severity.
Area of Science:
- Pediatric Dermatology
- Immunology
- Clinical Trials
Background:
- Atopic dermatitis (AD) severity varies across age groups.
- Typical lesion distribution in infants and young children is known, but correlations with disease severity metrics are underreported.
- Existing scoring systems for AD lack specific age-group validation.
Purpose of the Study:
- To assess clinical features of AD in infants and young children using the SCORAD index.
- To explore correlations between SCORAD parameters (extent, intensity, subjective symptoms) in this age group.
- To evaluate the utility of a simplified SCORAD scoring method for clinical practice.
Main Methods:
- The SCORAD index was applied to 63 infants and young children diagnosed with AD.
- Individual SCORAD parameters (erythema, edema, oozing/crust) were analyzed and compared.
- Serum eosinophil cationic protein (s-ECP) and urinary eosinophil protein X (u-EPX) levels were measured and correlated with SCORAD scores.
Main Results:
- Erythema, edema/papulation, and oozing/crust were prevalent findings in the study cohort.
- Significant positive correlations were observed among all SCORAD index parameters (extent, intensity, subjective symptoms).
- s-ECP and u-EPX levels demonstrated positive correlations with individual SCORAD parameters and the total score.
Conclusions:
- Infants and young children exhibit distinct AD intensity patterns.
- A strong correlation exists between AD extent, intensity, and subjective symptoms, all correlating with the total SCORAD score.
- Immunologic markers correlate with SCORAD components, reinforcing its role as the gold standard for AD severity assessment in clinical trials.
Background:
Atopic dermatitis (AD) affects infants, children, and adults with a wide degree of severity; several scoring systems have been used in trials and clinical practice. Infants and young children have a typical distribution of the lesions, but a correlation among skin surface involvement, intensity and subjective symptoms has not been reported in age groups.
Aims Of The Study:
To evaluate the clinical features of AD in infants and young children, by using the SCORAD index. A simplified scoring method for clinical practice is also discussed.
Methods:
The SCORAD index was assessed in 63 infants and young children with AD [mean age (+/-SD) 17.5 +/- 11.15 months]; the single parameters of the index were evaluated, and compared with each other. Serum eosinophil cationic protein (s-ECP) and urinary eosinophil protein X (u-EPX) levels were determined and correlated with the SCORAD index.
Results:
The presence of erythema, edema/papulation, and oozing/crust was significantly high in these patients. A strong positive correlation resulted among the three SCORAD index parameters (extent-intensity: P <0.001; extent-subjective symptoms: P <0.001; intensity-subjective symptoms: P <0.001). S-ECP and u-EPX levels positively correlated to almost every single parameter of the SCORAD index as well as to its total.
Conclusions:
Distinctive intensity items were found in infants and young children with AD. A strong correlation resulted among the extent, intensity, and subjective symptoms; each of the three parameters was positively correlated with the total SCORAD. Immunologic parameters positively correlated to each of the SCORAD index items, which remains the gold standard for assessing disease severity in clinical trials.
